BR112021023328A8 - Forma de cristal de composto de pirimidina sulfonamida e método de preparação para a mesma - Google Patents
Forma de cristal de composto de pirimidina sulfonamida e método de preparação para a mesmaInfo
- Publication number
- BR112021023328A8 BR112021023328A8 BR112021023328A BR112021023328A BR112021023328A8 BR 112021023328 A8 BR112021023328 A8 BR 112021023328A8 BR 112021023328 A BR112021023328 A BR 112021023328A BR 112021023328 A BR112021023328 A BR 112021023328A BR 112021023328 A8 BR112021023328 A8 BR 112021023328A8
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- crystal form
- sulfonamide compound
- compound crystal
- pyrimidine sulfonamide
- Prior art date
Links
- -1 PYRIMIDINE SULFONAMIDE COMPOUND Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000013078 crystal Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
FORMA DE CRISTAL DE COMPOSTO DE PIRIMIDINA SULFONAMIDA E MÉTODO DE PREPARAÇÃO PARA A MESMA. A presente invenção refere-se a uma forma de cristal (I) de um composto de pirimidina sulfonamida e um método de preparação para a mesma. A presente invenção refere-se a uma aplicação da mesma na preparação de um medicamento para o tratamento de doenças relacionadas a antagonistas de receptores de ETA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910428795 | 2019-05-22 | ||
| PCT/CN2020/091737 WO2020233694A1 (zh) | 2019-05-22 | 2020-05-22 | 一种嘧啶磺酰胺类化合物的晶型及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112021023328A2 BR112021023328A2 (pt) | 2022-04-12 |
| BR112021023328A8 true BR112021023328A8 (pt) | 2023-04-25 |
Family
ID=73458368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021023328A BR112021023328A8 (pt) | 2019-05-22 | 2020-05-22 | Forma de cristal de composto de pirimidina sulfonamida e método de preparação para a mesma |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220220098A1 (pt) |
| EP (1) | EP3974421B1 (pt) |
| JP (1) | JP2022533237A (pt) |
| CN (2) | CN118480033A (pt) |
| AU (1) | AU2020277546A1 (pt) |
| BR (1) | BR112021023328A8 (pt) |
| CA (1) | CA3139553A1 (pt) |
| DK (1) | DK3974421T3 (pt) |
| ES (1) | ES2988900T3 (pt) |
| FI (1) | FI3974421T3 (pt) |
| HR (1) | HRP20241310T1 (pt) |
| HU (1) | HUE068647T2 (pt) |
| IL (1) | IL288224A (pt) |
| LT (1) | LT3974421T (pt) |
| PL (1) | PL3974421T3 (pt) |
| PT (1) | PT3974421T (pt) |
| RS (1) | RS66002B1 (pt) |
| SM (1) | SMT202400383T1 (pt) |
| WO (1) | WO2020233694A1 (pt) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3490959B2 (ja) | 2000-07-11 | 2004-01-26 | 三洋電機株式会社 | 受光素子及び受光モジュール |
| CA2431675C (en) * | 2000-12-18 | 2011-11-08 | Actelion Pharmaceuticals Ltd. | Novel sulfamides and their use as endothelin receptor antagonists |
| DK3719013T3 (da) * | 2017-11-21 | 2023-04-03 | Wuxi Biocity Biopharmaceutics Co Ltd | Pyrimidinsulfamidderivat og fremgangsmdåde til fremstilling og medicinsk anvendelse heraf |
| CN109232546B (zh) * | 2018-09-25 | 2020-09-04 | 中国人民解放军总医院 | 一种嘧啶磺酰胺类衍生物的医药用途 |
-
2020
- 2020-05-22 CN CN202410593634.6A patent/CN118480033A/zh active Pending
- 2020-05-22 CN CN202080037909.8A patent/CN113874364B/zh active Active
- 2020-05-22 LT LTEPPCT/CN2020/091737T patent/LT3974421T/lt unknown
- 2020-05-22 EP EP20809241.1A patent/EP3974421B1/en active Active
- 2020-05-22 DK DK20809241.1T patent/DK3974421T3/da active
- 2020-05-22 HU HUE20809241A patent/HUE068647T2/hu unknown
- 2020-05-22 RS RS20241074A patent/RS66002B1/sr unknown
- 2020-05-22 BR BR112021023328A patent/BR112021023328A8/pt unknown
- 2020-05-22 FI FIEP20809241.1T patent/FI3974421T3/fi active
- 2020-05-22 PT PT208092411T patent/PT3974421T/pt unknown
- 2020-05-22 CA CA3139553A patent/CA3139553A1/en active Pending
- 2020-05-22 AU AU2020277546A patent/AU2020277546A1/en active Pending
- 2020-05-22 ES ES20809241T patent/ES2988900T3/es active Active
- 2020-05-22 JP JP2021569179A patent/JP2022533237A/ja active Pending
- 2020-05-22 SM SM20240383T patent/SMT202400383T1/it unknown
- 2020-05-22 WO PCT/CN2020/091737 patent/WO2020233694A1/zh unknown
- 2020-05-22 US US17/595,651 patent/US20220220098A1/en active Pending
- 2020-05-22 PL PL20809241.1T patent/PL3974421T3/pl unknown
- 2020-05-22 HR HRP20241310TT patent/HRP20241310T1/hr unknown
-
2021
- 2021-11-18 IL IL288224A patent/IL288224A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113874364B (zh) | 2024-04-05 |
| EP3974421B1 (en) | 2024-09-11 |
| BR112021023328A2 (pt) | 2022-04-12 |
| ES2988900T3 (es) | 2024-11-22 |
| HUE068647T2 (hu) | 2025-01-28 |
| AU2020277546A1 (en) | 2021-12-02 |
| HRP20241310T1 (hr) | 2024-12-20 |
| RS66002B1 (sr) | 2024-10-31 |
| US20220220098A1 (en) | 2022-07-14 |
| EP3974421A4 (en) | 2023-05-31 |
| FI3974421T3 (fi) | 2024-09-24 |
| JP2022533237A (ja) | 2022-07-21 |
| PT3974421T (pt) | 2024-10-03 |
| EP3974421A1 (en) | 2022-03-30 |
| PL3974421T3 (pl) | 2024-11-04 |
| LT3974421T (lt) | 2024-10-25 |
| WO2020233694A1 (zh) | 2020-11-26 |
| CN118480033A (zh) | 2024-08-13 |
| SMT202400383T1 (it) | 2024-11-15 |
| CA3139553A1 (en) | 2020-11-26 |
| CN113874364A (zh) | 2021-12-31 |
| IL288224A (en) | 2022-01-01 |
| DK3974421T3 (da) | 2024-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017002403A2 (pt) | formas de cristais de inibidores de glutaminase | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| MX2013012896A (es) | Compuestos novedosos como moduladores de proteina cinasas. | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| BR112013017316A2 (pt) | compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd) | |
| BR112014029868A2 (pt) | compostos, e, composição farmacêutica | |
| CR20140542A (es) | Anticuerpos biespecíficos anti-vegf7anti-ang-2 y su utilización en el tratamiento de enfermedades vasculares oculares | |
| BR112022001393A2 (pt) | Forma cristalina do inibidor de atr e seu uso | |
| CO2019006073A2 (es) | Estructura cristalina de gremlina 1 y anticuerpo inhibidor | |
| BR112017015852A2 (pt) | forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1 | |
| CO2021000932A2 (es) | Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma | |
| BR112016020260A8 (pt) | uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática | |
| BR112017006002A2 (pt) | compostos de imidazopiridazina e seu uso | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| BR112017010599A2 (pt) | análogos de ureia ligada substituída como moduladores sirtuin | |
| BR112017026272A2 (pt) | ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto? | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| BR112018014525A2 (pt) | compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112014009760A2 (pt) | análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo | |
| BR112022002632A2 (pt) | Sal e forma de cristal de composto que tem atividade de agonista do receptor s1p5 | |
| BR112021021230A8 (pt) | Forma de cristal de composto inibidor de wee1 e uso do mesmo | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| MX2017009514A (es) | Moduladores de los receptores a3 de adenosina. | |
| BR112021023328A8 (pt) | Forma de cristal de composto de pirimidina sulfonamida e método de preparação para a mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: WUXI BIOCITY BIOPHARMACEUTICS CO., LTD. (CN) |